Recently, a delegation of tumor therapists from Thailand, Indonesia, Vietnam and other countries arrived in Xiamen to visit the First Affiliated Hospital of Xiamen University, aiming to actively promote the exchange of innovative treatment achievements and clinical practice in the field of tumor in the "the Belt and Road" countries, and promote international exchange and scientific research cooperation in clinical practice of tumor immunotherapy. Currently, the scale of China's biopharmaceutical market has jumped to the second largest in the world, and the number of pharmaceutical innovation pipelines has entered the forefront of the world's second tier. Drug research and industrial development are entering a new stage of innovation breakthroughs. Especially in cutting-edge fields such as cell and gene therapy, as well as cancer, China has demonstrated tremendous potential and innovative vitality, occupying an increasingly important position in the global pharmaceutical industry chain. The "the Belt and Road" Initiative promotes international cooperation in tumor immunotherapy. This year is the first year of the second "Golden Decade" of the "the Belt and Road" Initiative. Cooperation and exchanges in the field of health care is an important part of the construction of the "the Belt and Road". It is not only related to the life and health of the people, but also an important bridge to promote friendly relations and common development among countries. It also bears the important mission of promoting the improvement of people's livelihood and health and well-being of countries along the Belt and Road. The countries jointly building the "the Belt and Road" have a huge population base and market capacity, and the pharmaceutical industry foundation is relatively weak, providing many opportunities for cooperation in the medical and health field. Diseases have no borders, and medical and health services rely more on close international exchanges Wang Zhanxiang, president of the First Affiliated Hospital of Xiamen University, said that Xiamen is an important window for foreign exchanges in Southeast China. Under the guidance of the country's strengthening and co building of health cooperation and exchanges among the "the Belt and Road" countries, we should actively commit to open exchanges and cooperation, and work together with ASEAN, Brazil and other countries to build a healthy future of a community with a shared future for mankind. At present, medical cooperation represented by tumor immunotherapy is increasingly becoming a new highlight of cooperation among countries jointly building the "the Belt and Road". Through sharing scientific research resources, exchanging clinical experience, and joint research and development, countries have carried out in-depth cooperation in the field of tumor immunotherapy. It is reported that the First Affiliated Hospital of Xiamen University has a national level standardized drug clinical trial institution, actively participates in new drug research and development, has a national tumor gene testing base, hosts and participates in international and domestic multi center clinical research, takes the lead in setting up Phase I clinical trial research wards in the province, carries out domestic and international first-class new drug research, involving multiple cutting-edge and popular fields such as targeted therapy, immunotherapy, cell therapy, etc. Clinical trials are at the leading level in China. Among them, the clinical evaluation demonstration platform for anti-tumor new drugs has received support from the National Science and Technology Major Special Project for the creation of major new drugs, making it the first national GCP demonstration platform in Fujian Province. Last year alone, the First Affiliated Hospital of Xiamen University conducted over 200 clinical studies and promoted the launch of more than 20 drugs. Since last year, several leading domestic pharmaceutical companies have successively launched innovative drugs to expand their presence in the global market, with Southeast Asia being a typical example of emerging markets. This transnational medical cooperation reflects the core concept of building a community of shared future and responsibility mentioned in the "the Belt and Road" initiative, which not only helps to improve the medical technology level of countries, but also provides patients with more treatment options and hopes; At the same time, it also promotes the optimization and sharing of medical resources, promoting the common development of the medical and health industry. The cooperation between ASEAN and China opens up new opportunities for tumor immunotherapy. ASEAN countries, as an important part of the global emerging biopharmaceutical market, are demonstrating enormous development potential. With the implementation of the Regional Comprehensive Economic Partnership Agreement, the economic and trade ties between China and ASEAN have become increasingly close, providing broad space for cooperation in the pharmaceutical industry. At present, the total population of the ten ASEAN countries exceeds 600 million, accounting for 8.5% of the global population, and there is a huge demand for innovative pharmaceutical and medical products. According to CPhI Insight data, the market size of the Southeast Asian pharmaceutical industry reached $40 billion in 2020, and it is expected that the annual revenue growth of the pharmaceutical industry will exceed 11% in the next five years. According to the 2022 Global Cancer Report released by the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), there are approximately 2.369 million new cases of cancer in Southeast Asia, with the majority of patients already in advanced stages at the time of diagnosis. In recent years, the internationalization of clinical diagnosis and treatment models for tumors and the globalization of innovative drug industries have not only brought tangible health benefits to the domestic population, but also provided useful references and guidance for global cancer prevention and control. Especially in the field of tumor immunotherapy, China has achieved significant research results, and multiple innovative drugs have been internationally recognized, providing more treatment options for ASEAN countries. Taking PD-1 (Programmed Death Receptor-1) as an example, PD-1 is a protein on human immune T cells. Unlike the therapeutic mechanism of traditional drugs, PD-1 inhibitors do not directly target tumor cells. Their main mechanism of action is to activate immune cells such as human T cells, and then fight against and eliminate tumor cells through immune responses. In recent years, with the breakthrough of PD-1 research and development, related products have gradually become first-line treatment drugs for various cancers. As of the end of 2023, the number of PD-1 monoclonal antibodies approved for market in China has reached 11, of which 9 are domestically produced. Domestic PD-1 antibodies have also expanded their overseas markets. Sullimumab was first launched in the Southeast Asian market at the end of 2023 and was approved for market in Indonesia. Multiple innovative drugs independently developed by China have been internationally recognized and will provide ASEAN countries with more and better treatment options. With the deepening of the "the Belt and Road" initiative, China and ASEAN use this platform to strengthen cooperation and exchanges in the pharmaceutical industry, jointly promote the innovation and development of the pharmaceutical industry, and thus inject new vitality into the development of the global pharmaceutical industry. In recent years, China has made significant progress in the field of tumor immunotherapy, thanks not only to the government's continuous investment in medical innovation and the introduction of a series of supportive policies, but also to the active layout of numerous innovative drug companies in the global market, which has contributed to China's strength on the international stage. By establishing extensive cooperative relationships with multiple countries and regions around the world, China has promoted the comprehensive internationalization of medical innovation. As one of the representatives of the innovative pharmaceutical industry, BeiGene has demonstrated strong capabilities in its global layout. The company has had in-depth cooperation with multiple countries and regions, including Australia, as early as the drug development stage. This global strategic layout not only provides BeiGene with broader market space and development opportunities, but also brings more diversified treatment options for cancer patients worldwide. Taking China Australia cooperation as an example, the close collaboration in drug clinical research has opened up more levels of cross-border exchange activities between China and Australia. The "China Australia Early Drug Research Summit Dialogue" in 2023 and the "China Australia Clinical Research Exchange Visit" in 2024 have been held successively, marking a new height of cooperation between China and Australia in the field of tumor immunotherapy. In these activities, experts and scholars from China and Australia gathered together to share their experiences in global multi center drug clinical research and the construction of research-oriented hospitals. At the same time, they provided a feasible path reference for the government industry university research full chain to support the transformation of clinical research achievements and achieve high-quality development in line with global standards. In addition to BeiGene, numerous enterprises and industrial institutions have also helped initiate cross national and regional medical exchange projects with Europe, America, Japan, South Korea, Asia Pacific, and other countries in recent years. These collaborations not only promote technological exchanges and talent cultivation, but also drive the development and internationalization of innovative drugs. In the wave of globalization, Chinese medical innovation is moving towards the world stage at an unprecedented speed and scale, with Chinese experts leading clinical research on innovative drugs approved in Europe and America. Cross border medical innovation practices are powerful weapons for humanity to tackle disease challenges. This ASEAN expert visit has also created a more suitable international exchange model for emerging market environments. Through sharing experiences and strengthening scientific research cooperation, the cooperation between the two sides in the field of tumor immunotherapy will be further deepened. Looking ahead, the global layout of China's tumor immunotherapy field will continue to deepen. Innovative pharmaceutical companies will continue to play a leading role in promoting international cooperation to a higher level. At the same time, Chinese medical institutions and researchers will actively participate in global multicenter clinical research and clinical achievement transformation, contributing more Chinese wisdom and strength to global cancer treatment and improving the health level of global patients. (New Society)